AEOI to Produce New Radiopharmaceuticals for Health Ministry
TEHRAN (Tasnim) – The Atomic Energy Organization of Iran has received an order to produce over 60 new radiopharmaceuticals for the domestic market, a spokesperson said.
AEOI Spokesman Behrouz Kamalvandi said on Tuesday that the Atomic Energy Organization has offered considerable assistance to the healthcare sector in recent years.
He noted that the AEOI has signed a contract with the Food and Drug Administration of the Health Ministry to produce 66 new radiopharmaceuticals.
A series of homegrown radiopharmaceuticals for the diagnosis and treatment of cancer are developed with world-class quality, he added.
In December 2022, the AEOI chief said Iran aims to become a global hub for manufacturing deuterium drugs.
“In a not too distant future we will turn into a hub for manufacturing drugs based on deuterium which are good alternatives to chemical drugs and have lower side effects in comparison (to those drugs),” he stated.
The AEOI launched a second phase of its deuterium production unit in Arak Heavy Water Reactor Facility in central Iran in April 2021.